Media coverage about MediciNova (NASDAQ:MNOV) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MediciNova earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 44.7713467212775 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of MediciNova (MNOV) opened at 6.58 on Friday. MediciNova has a 52-week low of $4.40 and a 52-week high of $7.78. The firm’s market cap is $230.75 million. The stock’s 50 day moving average price is $5.89 and its 200-day moving average price is $5.55.
In other MediciNova news, Director Yoshio Ishizaka bought 5,000 shares of the business’s stock in a transaction on Monday, August 21st. The shares were purchased at an average price of $5.17 per share, with a total value of $25,850.00. Following the completion of the acquisition, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $25,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thestockobserver.com/2017/10/13/medicinova-mnov-earning-somewhat-favorable-media-coverage-report-shows.html.
MediciNova Company Profile
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related companies with MarketBeat.com's FREE daily email newsletter.